Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000329700 | SCV000345899 | pathogenic | not provided | 2016-09-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001388197 | SCV001589069 | pathogenic | Fabry disease | 2020-12-22 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the GLA protein. Other variant(s) that disrupt this region (p.Ser345Argfs*29) have been determined to be pathogenic (PMID: 8931708, 23935525, Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with GLA-related conditions. ClinVar contains an entry for this variant (Variation ID: 291188). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Glu341Aspfs*7) in the GLA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 89 amino acid(s) of the GLA protein. |
Genome- |
RCV001388197 | SCV002054383 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |